Blood and marrow transplant for lymphoma patients with HIV/AIDS

Current Opinion in Oncology

Volumn 20, Issue 2, 2008, Pages 201-205

  Wagner Johnston, Nina D ^a   Ambinder, Richard F ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Autologous bone marrow stem cell transplantation; HIV AIDS; Non Hodgkin's lymphoma

Indexed keywords

ANTIINFECTIVE AGENT; ANTIRETROVIRUS AGENT; BLEOMYCIN; BUSULFAN; CARMUSTINE; CISPLATIN; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; MELPHALAN; METHYLPREDNISOLONE; PREDNISONE; RITUXIMAB; VINBLASTINE; VINCRISTINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AUTOLOGOUS STEM CELL TRANSPLANTATION; BACTERIAL INFECTION; BONE MARROW TRANSPLANTATION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DISEASE ASSOCIATION; DRUG MEGADOSE; GASTROINTESTINAL TOXICITY; GENE THERAPY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HODGKIN DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MUCOSA INFLAMMATION; NAUSEA; NONHODGKIN LYMPHOMA; PNEUMONIA; PRIORITY JOURNAL; RETINITIS; REVIEW; VIREMIA; WHOLE BODY RADIATION;

BONE MARROW TRANSPLANTATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIV INFECTIONS; HUMANS; LYMPHOMA, AIDS-RELATED; LYMPHOMA, NON-HODGKIN;

EID: 39849104009     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/CCO.0b013e3282f5101e     Document Type: Review

References (27)

1. Biggar RJ, Jaffe ES, Goedert JJ, et al. Hodgkin lymphoma and immunodeficiency in persons with HIV/AIDS. Blood 2006; 108:3786-3791.
2. Engels EA, Pfeiffer RM, Goedert JJ, et al. Trends in cancer risk among people with AIDS in the United States 1980-2002. Aids 2006; 20:1645-1654.
3. Gill PS, Levine AM, Krailo M, et al. AIDS-related malignant lymphoma: results of prospective treatment trials. J Clin Oncol 1987; 5:1322-1328.
4. Spina M, Jaeger U, Sparano JA, et al. Rituximab plus infusional cyclophosphamide, doxorubicin, and etoposide in HIV-associated non-Hodgkin lymphoma: pooled results from 3 phase 2 trials. Blood 2005; 105:1891-1897. Infusional chemotherapy with rituximab was associated with an excellent outcome. Increased bacterial infections were not noted. This was one of the first regimens to include rituximab.
5. Little RF, Pittaluga S, Grant N, et al. Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology. Blood 2003; 101:4653-4659.
6. Kaplan LD, Lee JY, Ambinder RF, et al. Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010. Blood 2005; 106:1538-1543. This study highlighted the potential infectious concerns with the addition of rituximab in regimens for HIV-associated lymphoma.
7. Weiss R, Mitrou P, Arasteh K, et al. Acquired immunodeficiency syndrome-related lymphoma: simultaneous treatment with combined cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy and highly active antiretroviral therapy is safe and improves survival - results of the German Multicenter Trial. Cancer 2006; 106:1560-1568.
8. Xicoy B, Ribera JM, Miralles P, et al. Results of treatment with doxorubicin, bleomycin, vinblastine and dacarbazine and highly active antiretroviral therapy in advanced stage, human immunodeficiency virus-related Hodgkin's lymphoma. Haematologica 2007; 92:191-198.
9. Spina M, Gabarre J, Rossi G, et al. Stanford V regimen and concomitant HAART in 59 patients with Hodgkin disease and HIV infection. Blood 2002; 100:1984-1988.
10. Bi J, Espina BM, Tulpule A, et al. High-dose cytosine-arabinoside and cisplatin regimens as salvage therapy for refractory or relapsed AIDS-related non-Hodgkin's lymphoma. J Acquir Immune Defic Syndr 2001; 28:416-421.
11. Re A, Cattaneo C, Michieli M, et al. High-dose therapy and autologous peripheral-blood stem-cell transplantation as salvage treatment for HIV-associated lymphoma in patients receiving highly active antiretroviral therapy. J Clin Oncol 2003; 21:4423-4427.
12. Krishnan A, Molina A, Zaia J, et al. Durable remissions with autologous stem cell transplantation for high-risk HIV-associated lymphomas. Blood 2005; 105:874-878. In this single institution study, Krishnan et al. included patients in complete response at high-risk for relapse. These investigators conclude that HIV should be likened to a chronic illness and that selection criteria for transplant should be similar to those used for lymphoma patients without HIV.
13. Serrano D, Carrion R, Balsalobre P, et al. HIV-associated lymphoma successfully treated with peripheral blood stem cell transplantation. Exp Hematol 2005; 33:487-494. This small multicenter Spanish study demonstrated the feasibility of AuSCT in patients with HIV-associated lymphoma.
14. Gabarre J, Marcelin AG, Azar N, et al. High-dose therapy plus autologous hematopoietic stem cell transplantation for human immunodeficiency virus (HIV)-related lymphoma: results and impact on HIV disease. Haematologica 2004; 89:1100-1108.
15. Spitzer TR, Ambinder RF, Lee JY, et al. Dose-reduced busulfan, cyclophosphamide and autologous stem cell transplantation for HIV-associated lymphoma: AIDS Malignancy Consortium Study 020. Biol Blood Marrow Transplant (in press).
16. Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995; 333:1540-1545.
17. Balsalobre P, Serrano D, Re A, et al. Autologous stem cell transplantation (ASCT) in HIV associated lymphoma (HIV-Ly) patients: The EBMT Lymphoma Working Party (EBMT-LWP) experience. Blood 2006; 108: abstract 3042.
18. Bower M, McCall-Peat N, Ryan N, et al. Protease inhibitors potentiate chemotherapy-induced neutropenia. Blood 2004; 104:2943-2946.
19. Sora F, Antinori A, Piccirillo N, et al. Highly active antiretroviral therapy and allogeneic CD34(+) peripheral blood progenitor cells transplantation in an HIV/HCV coinfected patient with acute myeloid leukemia. Exp Hematol 2002; 30:279-284.
20. Wolf T, Rickerts V, Staszewski S, et al. First case of successful allogeneic stem cell transplantation in an HIV-patient who acquired severe aplastic anemia. Haematologica 2007; 92:e56-e58.
21. Kang EM, de Witte M, Malech H, et al. Nonmyeloablative conditioning followed by transplantation of genetically modified HLA-matched peripheral blood progenitor cells for hematologic malignancies in patients with acquired immunodeficiency syndrome. Blood 2002; 99:698-701.
22. Schlegel P, Beatty P, Halvorsen R, McCune J. Successful allogeneic bone marrow transplant in an HIV-1-positive man with chronic myelogenous leukemia. J Acquir Immune Defic Syndr 2000; 24:289-290.
23. Holland HK, Saral R, Rossi JJ, et al. Allogeneic bone marrow transplantation, zidovudine, and human immunodeficiency virus type 1 (HIV-1) infection. Studies in a patient with non-Hodgkin lymphoma. Ann Intern Med 1989; 111:973-981.
24. Tomonari A, Takahashi S, Shimohakamada Y, et al. Unrelated cord blood transplantation for a human immunodeficiency virus-1-seropositive patient with acute lymphoblastic leukemia. Bone Marrow Transplant 2005; 36:261-262.
25. Gupta V, Tomblyn M, Pederson T, et al. Allogeneic hematopoietic stem cell transplantation in HIV-positive patients with malignant and nonmalignant disorders: a report from the center for International Blood and Marrow Transplant Research. Blood 2006; 108: abstract 5353.
26. Junker U, Moon JJ, Kalfoglou CS, et al. Hematopoietic potential and retroviral transduction of CD34+ Thy-1+ peripheral blood stem cells from asymptomatic human immunodeficiency virus type-1-infected individuals mobilized with granulocyte colony-stimulating factor. Blood 1997; 89:4299-4306.
27. Becker PS. The current status of gene therapy in autologous transplantation. Acta Haematol 2005; 114:188-197. Becker provides an excellent review of the state of the art in gene therapy and details the potential pitfalls with each of the various approaches.